Research focuses on next generation of powerful pain drugs | Study: Naked mole rats may hold clues to new pain treatments | Migraine may create permanent brain changes, study says
October 12, 2016
News for the pain professional
Pain Research News
Research focuses on next generation of powerful pain drugs
Researchers are developing a new generation of drugs that could have the pain-relieving power of opioids minus the dangerous side effects such as respiratory depression. Three compounds with potential are oliceridine, mitragynine pseudoindoxyl and PZM21, which bind to opioid receptors but activate different signaling pathways than current opioid drugs.
CNBC (10/12) 
LinkedIn Twitter Facebook Google+ Email
Study: Naked mole rats may hold clues to new pain treatments
Researchers are studying whether naked mole rats, which do not seem to feel certain types of pain, hold clues to developing new treatments for humans. A study in the journal Cell Reports is focused on thermal hyperalgesia, which the naked mole rats apparently do not experience at levels found in other animals.
The Washington Post (tiered subscription model) (10/11),  Deutsche Welle (Germany) (10/11) 
LinkedIn Twitter Facebook Google+ Email
Other News
NEW Pain Management Education Series – Save 10%
Essentials of Pain Management reviews the fundamentals of pain medicine including treatment of common pain disorders in clinical situations. This series will advance patient outcomes by providing continuing education to assess, treat and manage various pain disorders. Save 10%! Code: APS10. Learn more.
Treatment News
Study suggests spinal manipulation has placebo effect on migraine
Migraine relief from spinal manipulation therapy may be linked to a placebo effect, researchers reported in the European Journal of Neurology. The study found similar reductions in migraine days among patients in a spinal manipulation intervention group and a sham spinal manipulation group, and the benefits lasted longer than those for a group that received standard pharmacologic treatment.
MedPage Today (free registration) (10/10) 
LinkedIn Twitter Facebook Google+ Email
Low dose of Orexo's opioid dependence drug wins FDA nod
A lower dosage strength for Orexo's opioid dependence treatment Zubsolv, or buprenorphine/naloxone sublingual tablet, has been approved by the FDA. The drug will now be available in six strengths, including the new 0.7mg/0.18mg sublingual tablet. (10/6) 
LinkedIn Twitter Facebook Google+ Email
Other News
Policy & Trends
CDC: 14.6 million Americans report severe joint pain
CDC data show 14.6 million Americans reported severe joint pain in 2014, up from about 10.5 million in 2002. The study in the CDC's Morbidity and Mortality Weekly Report found severe joint pain was cited by 46% of adults with disabilities and 52% of those who said they were unable to work.
HealthDay News (10/6) 
LinkedIn Twitter Facebook Google+ Email
DEA mandates cut in opioid production
The Drug Enforcement Administration has ordered drugmakers to decrease production of prescription opioid medications by at least 25% next year, and production of some, including hydrocodone, must be cut by 34%. The decision follows recommendations from the CDC that health care professionals reduce prescribing of the drugs.
HealthDay News (10/5) 
LinkedIn Twitter Facebook Google+ Email
Other News
APS News
Present your research at the 2017 Annual Scientific Meeting!
The APS Scientific Program Committee (SPC) invites you to submit a poster abstract and present to hundreds of pain professionals at the 2017 Annual Scientific Meeting in Pittsburgh. The SPC is seeking original research that has not been previously presented or published elsewhere, prior to the APS meeting. All accepted posters will be presented at the 2017 Annual Scientific Meeting, May 17-20, 2017, and will be published in a supplement to The Journal of Pain. Submissions are due Tuesday, Nov. 15. Learn more.
LinkedIn Twitter Facebook Google+ Email
Nominate your APS leaders
The APS Nominating Committee solicits your nominations to elect the 2017-2018 Board of Directors and Nominating Committee. Nominees must be APS members and should demonstrate leadership qualities, have the ability to develop, communicate and sustain the Society's vision, possess strategic thinking and communications skills, and have a strong dedication to the society, its members, and the purposes APS serves. The deadline to nominate is Monday, Nov. 7. Learn more.
LinkedIn Twitter Facebook Google+ Email
It is an incalculable added pleasure to any one's sum of happiness if he or she grows to know, even slightly and imperfectly, how to read and enjoy the wonder-book of nature.
Theodore Roosevelt,
26th US president
LinkedIn Twitter Facebook Google+ Email
Learn more about APS:
Membership | Annual Meeting | Education
Funding Opportunities | About Us
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Lauren Barr
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information